Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells
Article first published online: 30 SEP 2011
© 2011 Japanese Cancer Association
Volume 102, Issue 12, pages 2157–2163, December 2011
How to Cite
Yamada, T., Bando, H., Takeuchi, S., Kita, K., Li, Q., Wang, W., Akinaga, S., Nishioka, Y., Sone, S. and Yano, S. (2011), Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Science, 102: 2157–2163. doi: 10.1111/j.1349-7006.2011.02093.x
- Issue published online: 20 NOV 2011
- Article first published online: 30 SEP 2011
- Accepted manuscript online: 5 SEP 2011 12:51AM EST
- (Received May 11, 2011/Revised August 24, 2011/Accepted September 1, 2011/Accepted manuscript online September 5, 2011)
Fig. S1. Detection of natural killer cells and macrophages in liver metastasis.
Fig. S2. Effects of mAbs BIW-8962, KM8927, and KM966 on the growth of SBC-3 small-cell lung cancer cells, as determined by MTT assays.
Fig. S3. Effects of KM8927 on antibody-dependent cellular cytotoxicity activity against SBC-3 small-cell lung cancer cells in the presence of human lymphocytes and monocytes, as determined by 4-h LDH releasing assays.
Fig. S4. Ganglioside GM2 expression in liver lesions produced by small-cell lung cancer SBC-3 cells treated with or without KM8927.
|CAS_2093_sm_fS1.pdf||104K||Supporting info item|
|CAS_2093_sm_fS2.pdf||51K||Supporting info item|
|CAS_2093_sm_fS3.pdf||33K||Supporting info item|
|CAS_2093_sm_fS4.pdf||519K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.